Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age — B1971042  

Meningitis, Meningococcal, Serogroup B Clinical Trial

Official title: A Single-arm, Open-label Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers >=18 To < =65 Years Of Age

Status Completed

Clinical Trial Summary

This study will assess the safety, tolerability and immunogenicity of bivalent rLP2086 vaccine in laboratory workers ≥18 to ≤65 years of age administered on a Month 0, 2, and 6 schedule. The study will recruit laboratory personnel (inclusive of Pfizer staff) who work directly with pathogenic Neisseria meningitidis in the context of the bivalent rLP2086 vaccine development program. The study will provide descriptive safety and immunogenicity data following vaccination of these individuals with bivalent rLP2086 vaccine.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Meningitis
• Meningitis, Meningococcal
• Meningitis, Meningococcal, Serogroup B

• NCT number: NCT01768117
• Study type: Interventional
• Source: Pfizer
• Status: Completed
• Phase: Phase 2
• Start date: February 2013
• Completion date: February 2014